Market Intelligence Center  Aug 10  Comment 
MarketIntelligenceCenter.com's patented trade-picking algorithms have identified an attractive covered-call trade on Exelixis (EXEL). Look at the Feb 15, 2019 $19 covered call for a net debit in the $17 area. This trade has a duration of 189 days....
Motley Fool  Aug 6  Comment 
Competing with immuno-oncology drugs might be hard, but being used after them is easy.
Motley Fool  Aug 2  Comment 
The company hopped over investors' wall of worry.
Yahoo  Aug 1  Comment 
Exelixis (EXEL) delivered earnings and revenue surprises of 86.67% and 21.39%, respectively, for the quarter ended June 2018. Do the numbers hold clues to what lies ahead for the stock?
Yahoo  Aug 1  Comment 
The South San Francisco, California-based company said it had net income of 28 cents per share. The results surpassed Wall Street expectations. The average estimate of six analysts surveyed by Zacks Investment ...
Motley Fool  Aug 1  Comment 
See why a music streaming leader, a cancer-drug developer, and a retail outlet REIT are compelling buys today.
Market Intelligence Center  Jul 31  Comment 
MarketIntelligenceCenter.com's patented trade-picking algorithms have identified an attractive covered-call trade on Exelixis (EXEL). Look at the Feb 15, 2019 $19 covered call for a net debit in the $16.96 area. This trade has a duration of 199...


Exelixis (NYSE: EXEL) is a drug discovery and development company that earns revenue from the out-licensing of potential therapies that it discovers to big pharma collaborators. In 2010, Bristol-Myers Squibb Company (BMY) returned the rights to develop cancer drug, Cabozantinib, back to Exelixis.[1] Since acquiring full rights to Cabozantinib, Exelixis has focused much of its operations on the development of the compound.

The valuation of Exelixis depends significantly on the progress of the clinical trials that it is conducting for cabozantinib.

Business Growth (For the fiscal year ending December 31, 2010)[2]

  • Revenue increased 22% to $185 million
  • Net loss decreased 32% to $92 million

Revenue growth in 2010 was largely due to payments from collaborations with Sanofi-Aventis SA (SNY) and Bristol-Myers Squibb Company (BMY). In 2011, Exelixis expects revenues in the range of $145-160 million, with expenses of $190-220 million.[3]


Exelixis is developing its lead compound, cabozantinib, to treat a variety of cancers:

  • Phase III: Exelixis has begun phase III clinical trials to evaluate the use of cabozantinib to treat patients with Medullary Thyroid Cancer.
  • Phase II: Exelixis has begun non-randomized studies to evaluate the use of cabozantinib to treat patients with ovarian cancer and a form of Prostate Cancer. In addition, Exelixis has begun randomized trials to evaluate cabozantinib in Breast Cancer, Gastric/GE Junctional Cancer, Hepatocellular Carcinoma, Melanoma, Castration-Resistant Prostate Cancer, Lung Cancer, Ovarian Cancer, and Pancreatic Cancer.
  • Phase I: Exelixis is evaluating cabozantinib in Phase I trials to treat patients with Differentiated Thyroid Cancer and Renal Cell Carcinoma.

Trends and Forces

Exelixis Needs to Obtain Regulatory Approval in Order to Earn Significant Revenue

To date, all of Exelixis's revenue has been earned from milestone and royalty payments paid by pharmaceutical partners. In order to make the full transition from a development-stage company to a fully commercial pharmaceutical company, Exelixis needs to obtain regulatory approval for cabozantinib. Exelixis is currently in the midst of phase III clinical trials, which are the final, but most costly and risky stage of clinical development. Exelixis expects to receive an FDA decision on the use of cabozantinib to treat medullary thyroid cancer by the end of 2012.[4]

Exelixis's Ability to Develop Cabozantinib for Multiple Cancers will Impact Revenue

Exelixis is currently develop cabozantinib as a therapy for 13 different types of cancer.[5] Each of these cancer types represents a new market and additional revenue for Exelixis down the road. Exelixis's ability to obtain FDA approval for these additional markets will impact its bottom line.


  • AstraZeneca (AZN): In April of 2011, Vandetanib was approved by the FDA to treat patients with medullary thyroid cancer, the leading indication for Cabozantinib.[6]
  • Roche Pharmaceuticals (RHHBY): Manufactures Avastin, a cancer drug that works using a similar mechanism as cabozantinib. Avastin is approved to treat several forms of cancer, including lung cancer, breast cancer, and colon cancer.[7]
  • GlaxoSmithKline (GSK): Manufactures Tykerb, a cancer drug with a similar mechanism of action as cabozantinib that is approved to treat breast, lung, and oral cancer.[8]


  1. Bristol-Myers Squibb returns rights to Exelixis cancer drug
  2. EXEL 2011 10K
  3. Exelixis Announces Fourth Quarter and Full Year 2010 Financial Results
  4. Exelixis Provides Update on Cabozantinib Development Activities
  5. Exelixis Clinical Trial Information
  6. AstraZeneca Gets FDA Approval For Cancer Drug Vandetanib
  7. Bevacizumab Injection
  8. Lapatinib
Wikinvest © 2006, 2007, 2008, 2009, 2010, 2011, 2012. Use of this site is subject to express Terms of Service, Privacy Policy, and Disclaimer. By continuing past this page, you agree to abide by these terms. Any information provided by Wikinvest, including but not limited to company data, competitors, business analysis, market share, sales revenues and other operating metrics, earnings call analysis, conference call transcripts, industry information, or price targets should not be construed as research, trading tips or recommendations, or investment advice and is provided with no warrants as to its accuracy. Stock market data, including US and International equity symbols, stock quotes, share prices, earnings ratios, and other fundamental data is provided by data partners. Stock market quotes delayed at least 15 minutes for NASDAQ, 20 mins for NYSE and AMEX. Market data by Xignite. See data providers for more details. Company names, products, services and branding cited herein may be trademarks or registered trademarks of their respective owners. The use of trademarks or service marks of another is not a representation that the other is affiliated with, sponsors, is sponsored by, endorses, or is endorsed by Wikinvest.
Powered by MediaWiki